Related Experiment Video

Updated: Dec 26, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.3K

Erlotinib

Ahmed A Abdelgalil1, Hamad M Al-Kahtani2, Fahad I Al-Jenoobi3

  • 1Central Laboratory, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.

Profiles of Drug Substances, Excipients, and Related Methodology
|March 14, 2020
PubMed

Insights

Erlotinib (Tarceva®) is an anticancer drug targeting EGFR to treat Non-Small Cell Lung Cancer and Pancreatic Cancer. This study details its comprehensive profile, analysis, and pharmacology.

Area of Science:

  • Oncology
  • Pharmacology
  • Analytical Chemistry

Background:

  • Erlotinib (Tarceva®) is an FDA-approved anticancer drug.
  • It targets the epidermal growth factor receptor (EGFR) to inhibit tumor cell proliferation.
  • The drug is indicated for Non-Small Cell Lung Cancer (NSCLC) and Pancreatic Cancer.

Purpose of the Study:

  • To provide a comprehensive profile of erlotinib.
  • To detail its chemical, physical, and analytical characteristics.
  • To present its pharmacological properties, including mechanism of action and pharmacokinetics.

Main Methods:

  • Physico-chemical characterization.
  • Spectroscopic analyses (UV/vis, vibrational, NMR, mass spectrometry).
  • Chromatographic analyses (TLC, HPLC).
  • Pharmacological profiling (pharmacodynamics, pharmacokinetics, drug-drug interactions).

Main Results:

  • Detailed nomenclature, formula, and elemental analysis provided.
  • Physico-chemical properties characterized.
  • Multiple analytical methods (spectroscopic, chromatographic) validated.
  • Pharmacological data including mechanism of action, pharmacokinetics, and drug interactions presented.

Conclusions:

  • This study offers a thorough characterization of erlotinib.
  • It consolidates essential information for researchers and clinicians.
  • The comprehensive profile aids in understanding erlotinib's therapeutic applications and behavior.
Keywords:
Cancer drugDrug-drug interactionsErlotinibNon-small cell lung cancer (NSCLC) and pancreatic cancerTyrosine kinase inhibitors

More Related Videos

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

337
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

761

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
379
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
369
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.6K